Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.101 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023263% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001346% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.036 |
| Open | 2.956 |
| 1-Year Change | 53.4% |
| Day's Range | 2.862 - 3.021 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 2.947 | -0.009 | -0.30% | 2.956 | 3.036 | 2.862 |
| Apr 16, 2025 | 3.036 | 0.124 | 4.26% | 2.912 | 3.041 | 2.862 |
| Apr 15, 2025 | 2.986 | 0.139 | 4.88% | 2.847 | 3.036 | 2.837 |
| Apr 14, 2025 | 2.832 | -0.020 | -0.70% | 2.852 | 2.937 | 2.822 |
| Apr 11, 2025 | 2.782 | 0.115 | 4.31% | 2.667 | 2.802 | 2.652 |
| Apr 10, 2025 | 2.727 | 0.350 | 14.72% | 2.377 | 2.887 | 2.372 |
| Apr 9, 2025 | 2.327 | -0.090 | -3.72% | 2.417 | 2.457 | 2.287 |
| Apr 8, 2025 | 2.542 | 0.125 | 5.17% | 2.417 | 2.557 | 2.417 |
| Apr 7, 2025 | 2.452 | -0.020 | -0.81% | 2.472 | 2.597 | 2.357 |
| Apr 4, 2025 | 2.572 | -0.100 | -3.74% | 2.672 | 2.672 | 2.472 |
| Apr 3, 2025 | 2.637 | 0.005 | 0.19% | 2.632 | 2.757 | 2.627 |
| Apr 2, 2025 | 2.747 | -0.125 | -4.35% | 2.872 | 2.872 | 2.647 |
| Apr 1, 2025 | 2.917 | 0.020 | 0.69% | 2.897 | 2.962 | 2.822 |
| Mar 31, 2025 | 2.977 | -0.069 | -2.27% | 3.046 | 3.051 | 2.897 |
| Mar 28, 2025 | 3.101 | 0.075 | 2.48% | 3.026 | 3.111 | 2.966 |
| Mar 27, 2025 | 3.041 | 0.035 | 1.16% | 3.006 | 3.101 | 2.976 |
| Mar 26, 2025 | 3.026 | 0.010 | 0.33% | 3.016 | 3.091 | 2.946 |
| Mar 25, 2025 | 3.006 | -0.005 | -0.17% | 3.011 | 3.056 | 2.897 |
| Mar 24, 2025 | 3.006 | -0.040 | -1.31% | 3.046 | 3.046 | 2.897 |
| Mar 21, 2025 | 3.041 | 0.050 | 1.67% | 2.991 | 3.041 | 2.941 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Oxford BioMedica plc Company profile
About Oxford BioMedica plc
Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Financial summary
BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.
Equity composition
10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).
| Industry: | Bio Therapeutic Drugs |
Windrush Court
Transport Way
OXFORD
OXFORDSHIRE OX4 6LT
GB
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com